Article contents
Assessing the utility of universal preprocedure severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) testing at a cancer center
Published online by Cambridge University Press: 07 April 2022
Abstract
We implemented preprocedure severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing for cancer patients. The overall positivity rate was 0.3%. Preprocedure testing may be limited to operative procedures as community rates of SARS-CoV-2 exceed 7%. Nonoperative aerosol-generating procedures may be performed without preprocedure testing, wearing the appropriate personal protective equipment.
- Type
- Concise Communication
- Information
- Copyright
- © The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
References
- 4
- Cited by